NASDAQ:HALO - Halozyme Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.64 +0.15 (+0.97 %) (As of 03/25/2019 02:48 PM ET)Previous Close$15.49Today's Range$15.2450 - $15.6652-Week Range$13.24 - $20.54Volume344,964 shsAverage Volume914,499 shsMarket Capitalization$2.27 billionP/E Ratio-27.94Dividend YieldN/ABeta1.87 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California. Receive HALO News and Ratings via Email Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO Previous Symbol CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Debt Debt-to-Equity Ratio0.14 Current Ratio2.86 Quick Ratio2.71Price-To-Earnings Trailing P/E Ratio-27.94 Forward P/E Ratio-36.38 P/E GrowthN/A Sales & Book Value Annual Sales$151.86 million Price / Sales14.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book9.10Profitability EPS (Most Recent Fiscal Year)($0.56) Net Income$-80,330,000.00 Net Margins-52.90% Return on Equity-31.86% Return on Assets-17.32%Miscellaneous Employees281 Outstanding Shares145,030,000Market Cap$2.27 billion Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Thursday, February, 21st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The biopharmaceutical company had revenue of $60.23 million for the quarter, compared to analyst estimates of $59.77 million. Halozyme Therapeutics had a negative net margin of 52.90% and a negative return on equity of 31.86%. The firm's revenue was down 68.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.85 EPS. View Halozyme Therapeutics' Earnings History. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Halozyme Therapeutics. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics issued an update on its FY 2019 earnings guidance on Thursday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205-215 million, compared to the consensus revenue estimate of $168.78 million. What price target have analysts set for HALO? 5 Wall Street analysts have issued 12-month price objectives for Halozyme Therapeutics' shares. Their predictions range from $17.00 to $24.00. On average, they anticipate Halozyme Therapeutics' share price to reach $20.40 in the next year. This suggests a possible upside of 30.9% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics. What is the consensus analysts' recommendation for Halozyme Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Halozyme Therapeutics. What are Wall Street analysts saying about Halozyme Therapeutics stock? Here are some recent quotes from research analysts about Halozyme Therapeutics stock: 1. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (2/6/2019) 2. Cantor Fitzgerald analysts commented, "We are OW with a $24 PT. The ENHANZE partnerships have recently expanded & include multiple shots on goal, with the reformulation of JNJ’s DARZALEX in P3 studies being most advanced. We believe these partnerships represent multiple value inflection points and, almost irrespective of the outcome of PC, drive our favorable perspective." (2/4/2019) Has Halozyme Therapeutics been receiving favorable news coverage? Media headlines about HALO stock have been trending positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the company's share price in the next few days. Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP) and Denali Therapeutics (DNLI). What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), Gilead Sciences (GILD), BlackRock (BLK), Micron Technology (MU), Chipotle Mexican Grill (CMG), General Electric (GE), Celgene (CELG), Synergy Pharmaceuticals (SGYP) and Allergan (AGN). Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the folowing people: Dr. Helen I. Torley, Pres, CEO & Director (Age 56)Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44) Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.13%), Iridian Asset Management LLC CT (6.24%), BB Biotech AG (5.76%), Thrivent Financial for Lutherans (2.46%), FMR LLC (1.77%) and Northern Trust Corp (1.22%). View Institutional Ownership Trends for Halozyme Therapeutics. Which major investors are selling Halozyme Therapeutics stock? HALO stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Two Sigma Investments LP, Prudential Financial Inc., Two Sigma Advisers LP, Iridian Asset Management LLC CT, Commonwealth Equity Services LLC, BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Halozyme Therapeutics. Which major investors are buying Halozyme Therapeutics stock? HALO stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Thrivent Financial for Lutherans, Fisher Asset Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Arete Wealth Advisors LLC and Granite Investment Partners LLC. View Insider Buying and Selling for Halozyme Therapeutics. How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $15.58. How big of a company is Halozyme Therapeutics? Halozyme Therapeutics has a market capitalization of $2.26 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe. What is Halozyme Therapeutics' official website? The official website for Halozyme Therapeutics is http://www.halozyme.com. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected] MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 352 (Vote Outperform)Underperform Votes: 313 (Vote Underperform)Total Votes: 665MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: Are FAANG stocks a good investment?